DiaMedica Therapeutics宣布其Remedy2急性缺血性卒中2/3期试验达到75%患者入组里程碑

美股速递
May 20

DiaMedica Therapeutics Inc. (DMAC) 宣布,其针对急性缺血性卒中的关键性Remedy2 2/3期临床试验,已成功达到75%的患者入组目标。这一进展标志着该试验在推进评估其先导候选药物DM199疗效的进程中,迈出了重要一步。该试验旨在验证DM199在改善卒中患者神经功能恢复方面的潜力,其阶段性成果为后续的数据收集与分析奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10